CPhI announces Innovation Awards finalists
The organisers of CPhI, UBM, have revealed the six finalists of the CPhI Innovation Awards. The finalists were chosen based on innovation and commercial practicality.
The organisers of CPhI, UBM, have revealed the six finalists of the CPhI Innovation Awards. The finalists were chosen based on innovation and commercial practicality.
3M Drug Delivery Systems for an Integrated Dose by Dose counter that enables patients to track the number of remaining doses in their inhaler.
Acuros for a novel disposable device for the continuous delivery of small volume parenteral drugs. The device uses an osmotic actuation and does not require a power supply.
Gerresheimer for its high-performance plastic vial made from cyclic olefin polymer and polyamide using multilayer technology for parenteral products.
Glycotope for the GlycoExpress platform technology, which helps optimise glycosylation of antibodies and other glycosylated therapeutics.
Johnson Matthey Catalysts for its Colour-Tag-Protein technology. The technology can be used as a direct marker for protein expression to speed up the development of new bioprocesses.
PANATecs for the P-Check technique, which uses fluorescence resonance energy transfer technology to detect whether materials contain protease contamination.
The finalists will each make a 20-minute presentation on Tuesday 25 October between 10 am and 12.50 pm at booth 51DO2. It’s free to attend so don’t miss out!
The winners and runners up will be announced at the Exhibitor Party, which will be held later that day (5.30–7.30 pm) in the Europa hall.
Which do you think will win? Let us know your thoughts on our LinkedIn group!
The awards first began in 2004 and this year’s show in Frankfurt will mark their eighth anniversary. The awards were established to recognise, celebrate and honour companies and organisations breaking new ground in the pharmaceutical, contract services, packaging and biopharmaceutical industries. The entry categories were open to all exhibitors at CPhI and its collocated events.
More information about the awards is available on the CPhI website:
www.cphi.com/innovation-awards
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
The Role of Forced Degradation in Method Development, Manufacturability, and CMC Strategy
April 28th 2025Forced degradation studies are critical in biologics development, particularly for monoclonal antibodies (mAbs). These studies simulate long-term environmental stressors to uncover degradation pathways and ensure the stability of critical quality attributes (CQAs), aiding in robust chemistry, manufacturing, and controls (CMC) strategies and regulatory compliance.
Advancing Clinical Trials with Spectral Flow Cytometry: A Conversation with Kevin Lang
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
